摘要
目的对某院2019~2022年4年内的药品不良反应回顾性流行病学调查分析,为临床安全用药提供理论参考。方法从该院ADR监测系统中收集2019~2022年上报的药物不良反应报告的数据,采用回顾性流行病学研究方法进行分析。结果发生药物不良反应人群中老年人比例比年轻人高;大多数药物不良反应时间在用药后的3 d内(62.02%);静脉和口服给药是发生ADR的主要给药途径;ADR药物品种以抗菌药物和抗肿瘤药物为主;ADR累及器官或系统发生率依次是消化系统、血液系统、皮肤及其附件和中枢神经系统;ADR发生的抗菌药物使用较多依次是β-内酰胺类/β-内酰胺酶抑制剂、喹诺酮类、碳青霉烯类。结论该院应加强对老年患者ADR监测,重视静脉和口服给药途径,同时将抗菌药物和抗肿瘤药物用药安全作为监测工作中的重点。
OBJECTIVE To analyze the retrospective epidemiological investigation of adverse drug reactions(ADRs) in the hospital over a 4-year period from 2019-2022,providing theoretical references for the safe use of medication in the clinic.METHODS Data on adverse drug reaction reports reported from 2019 to 2022 were collected from the hospital ADR monitoring system and analyzed using a retrospective epidemiological study.RESULTS The proportion of elderly people who had ADRs was higher than that of young people,most of the ADRs occurred within 3 days(62.02%).Intravenous and oral administration were the main ways of administration for the occurrence of ADRs.ADRs were caused mainly by using antimicrobials and antitumour drugs.The rate of organ or system involved in ADRs were followed by the gastrointestinal system,haematological system,skin and its adnexa,and central nervous system.ADRs occurred more frequently with the use of β-lactams/β-lactamase inhibitors,quinolones,and carbapenems in order.CONCLUSION ADR monitoring of elderly patients should be strengthened in the hospital,with emphasis on intravenous and oral routes of administration,at the same time the safety of antimicrobial and antineoplastic drug use should be a priority in the monitoring process.
作者
劳楚瑜
李子焕
王钰琦
陈杰
LAO Chuyu;LI Zihuan;WANG Yuqi;CHEN Jie(Department of Pharmacy,The First Affiliated Hospital of Sun Yat-sen University,Guangzhou,Guangdong 510080,China;Department of Healthcare-associated Infection Management,Guangdong Second Provincial General Hospital,Guangzhou,Guangdong 510310,China)
出处
《今日药学》
CAS
2023年第12期945-949,共5页
Pharmacy Today
基金
广东省基础与应用基础研究基金企业联合基金(2021A1515220165)。
关键词
药物不良反应
药物警戒系统
抗菌药物
adverse drug reaction
pharmacovigilance system
antibacterial drug